European equities traded in the US as American depositary receipts were lower late Friday morning, declining 0.40% to 1,494.86 on the S&P Europe Select ADR Index, which is up 1.6% for the week.
From continental Europe, the gainers were led by biopharmaceutical companies Cellectis (CLLS) and DBV Technologies (DBVT), which advanced 27% and 3.3%, respectively. They were followed by medical device maker EDAP (EDAP) and biopharmaceutical company Grifols (GRFS), which increased 2.1% and 1.3%, respectively.
The decliners from continental Europe were led by semiconductor company Sequans Communications (SQNS) and biotech firm Evaxion (EVAX), which fell 4.7% and 4.1%, respectively. They were followed by petroleum refiner Equinor (EQNR) and accommodations booking company trivago (TRVG), which dropped 1.2% and 1%, respectively.
From the UK and Ireland, the gainers were led by biopharmaceutical company Adaptimmune Therapeutics (ADAP) and pharmaceutical company Silence Therapeutics (SLN), which rose 4.8% and 2.3%, respectively. They were followed by biopharmaceutical company Mereo BioPharma Group (MREO) and financial services company Lloyds Banking Group (LYG), which were up 1.7% and 1.5%, respectively.
The decliners from the UK and Ireland were led by biotech firm Trinity Biotech (TRIB) and mining company BHP Group (BHP), which were down 4% and 1.8%, respectively. They were followed by pharmaceutical company GSK (GSK) and telecommunications operator Vodafone Group (VOD), which lost 1.7% each.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。